Safety and preliminary immunogenicity of the recombinant outer membrane protein P64K of Neisseria meningitidis in human volunteers

Biotechnology and Applied Biochemistry

Volumn 34, Issue 2, 2001, Pages 121-125

  Perez A ^a   Dickinson, F ^a   Cinza, Z ^a   Ruiz A ^a   Serrano, T ^a   Sosa, J ^a   Gonzalez S ^a   Gutierrez Y ^a   Nazabal C ^a   Gutierrez O ^a   Guzman D ^a   Diaz M ^a   Delgado, M ^a   Caballero, E ^a   Sardinas G ^a   Alvarez, A ^a   Martin A ^a   Guillen G ^a   Silva, R ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Carrier protein; Clinical trial

Indexed keywords

POTENT BOOSTER;

ANTIBODIES; ANTIGENS; BIOLOGICAL MEMBRANES; DNA; VACCINES;

PROTEINS;

ANTIGEN; CARRIER PROTEIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PLACEBO; PROTEIN P64K; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VA MENGOC BC;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NAUSEA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL CHEMISTRY; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECOMBINANT DNA TECHNOLOGY; VACCINATION; VOMITING;

ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION SCHEDULE; MALE; NEISSERIA MENINGITIDIS; RECOMBINANT PROTEINS;

MENINGOCOCCUS; NEISSERIA MENINGITIDIS;

EID: 17944377380     PISSN: 08854513     EISSN: None     Source Type: Journal    
DOI: 10.1042/BA20010029     Document Type: Article

References (24)